Encorafenib is a selective BRAF kinase inhibitor indicated for the treatment of unresectable or metastatic melanoma characterized by specific V600E or V600K mutations. It functions by blocking the BRAF… Read more








![Chemical structure of Di-tert-butyl (5,5'-dichloro-2,2'-difluoro-[1,1'-biphenyl]-3,3'-diyl)dicarbamate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2FDi-tert-butyl-55-dichloro-22-difluoro-11-biphenyl-33-diyldicarbamate.png&w=3840&q=75)
































Encorafenib is a selective BRAF kinase inhibitor indicated for the treatment of unresectable or metastatic melanoma characterized by specific V600E or V600K mutations. It functions by blocking the BRAF protein, effectively inhibiting the signaling pathways responsible for tumor growth and survival in patients with these genetic alterations. To ensure stringent quality control and regulatory compliance during pharmaceutical manufacturing, access to high-quality reference standards is essential. This category includes a comprehensive selection of Encorafenib impurities, degradation products, and stable isotope labelled compounds required for precise analytical testing. These materials are vital for impurity profiling, allowing laboratories to detect and quantify structurally related analogs, including those resulting from hydrolytic or oxidative pathways. Furthermore, stable isotope labelled standards act as internal standards for mass spectrometry-based assays, facilitating accurate method validation and consistency throughout the drug development lifecycle.